Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Colchicine in Chronic Limb-Threatening Ischemia

A legfontosabb adatok

Ki végzi
Shin Kong Wu Ho-Su Memorial Hospital
Hol
Tajvan5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
200 fő, tervezett
Kezdés
2026. jún. 2.
Várható befejezés
2030. ápr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Colchicine 0.5 MG Oral Tablet Once Daily
  • Placebo
A regiszteradat frissítve
2026. július 14.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with chronic limb-threatening ischemia, a severe lack of blood flow to the leg. They must have had a successful procedure to restore blood flow to the leg in the last 7 days.

Életkor
18 years and older.
Nem
All sexes can join.
A betegség stádiuma
Chronic limb-threatening ischemia with gangrene, a wound that does not heal, or leg pain at rest (Rutherford classes 4-5). There must be imaging from the past 12 months showing narrowed arteries from fatty build-up (atherosclerotic PAD).
Korábbi kezelés
A successful procedure to open the blocked artery (endovascular therapy) or bypass surgery within the last 7 days before joining. It must be the last planned procedure on that leg, with blood flow to the foot shown afterwards and no plan for another procedure soon.
Biomarker vagy leletérték
Ankle-Brachial Index (ABI) ≤0.80 or Toe-Brachial Index (TBI) ≤0.60 if no earlier procedure; ABI ≤0.85 or TBI ≤0.65 after an earlier procedure. Or low pressure readings: for rest pain, ankle pressure <50 mmHg, toe pressure <30 mmHg or transcutaneous PO2 <30 mmHg; for tissue loss, ankle pressure <70 mmHg, toe pressure <50 mmHg or transcutaneous PO2 <30 mmHg.

A részvétel fő kizáró okai

  • Mild or no symptoms (Rutherford classes 0-3), or major tissue loss (Rutherford 6) with a planned major amputation.
  • Severe uncontrolled leg infection or blood infection, or sudden blocked blood flow to the leg in the last 2 weeks.
  • Heart attack-type event, acute stroke, or hospital stay for heart failure within 30 days.
  • Cannot take colchicine or antiplatelet medicines, needs colchicine for another reason, or takes medicines that interact with colchicine.
  • Pregnancy, breastfeeding, active hepatitis, severe liver cirrhosis (Child Pugh C), or life expectancy <1 year.

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years
  • Documented chronic limb-threatening ischemia, meeting the following:; Presence of ischemic symptoms compatible with CLTI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford classes 4-5 AND; Imaging evidence within the past 12 months showing atherosclerotic PAD, including CTA, MRA, angiography or duplex ultrasound AND; Ankle-Brachial Index (ABI) ≤0.80 or Toe-Brachial Index (TBI) ≤0.60 for patients without prior revascularization; ABI ≤0.85 or TBI ≤0.65 for those with prior revascularization OR; Ischemic rest pain alone (Rutherford class 4) defined as ankle systolic pressure <50 mmHg, toe pressure of <30 mmHg, transcutaneous PO2 of <30 mmHg, or flat-line transtarsal pulse volume recording OR; Tissue loss with or without ischemic rest pain (Rutherford class 5) defined as ankle systolic pressure <70 mmHg, toe pressure of <50 mmHg, transcutaneous PO2 of <30 mmHg, or flatline transtarsal pulse volume recording
  • Recent successful revascularization:; Underwent technically successful endovascular therapy (EVT) or surgical bypass within the last 7 days prior to randomization; For individuals requiring multiple revascularization attempts on the same index leg, the procedure considered for eligibility (in other words, the qualifying or index procedure) must be the final planned or anticipated revascularization attempt; There must be demonstrated graft or vascular patency after the qualifying revascularization procedure with one in-line blood flow to the foot, either by angiography, duplex ultrasound, CTA or MRA; There must be no immediate plan for reintervention
  • Informed Consent:; Demonstrated ability and willingness to adhere to the study protocol, attend scheduled follow-up visits, complete all required assessments, and provide written informed consent

Ki nem vehet részt

  • Need for use of medications known to have drug-drug interactions with colchicine, particularly drugs known to inhibit CYP3A4 or P-glycoprotein
  • Previous (within 30 days) or concomitant participation in another clinical study with investigational medicinal product(s)
  • Asymptomatic or mild disease: Patients who underwent revascularization for disease graded Rutherford classes 0-3
  • Failure to establish at least one tibial artery outflow after revascularization
  • Unable to tolerate any antiplatelet agent or with severe bleeding diathesis
  • Acute coronary syndrome, acute stroke, or hospitalization for heart failure within 30 days of screening
  • Active hepatitis or severe liver cirrhosis (Child Pugh C)
  • Clinical signs of active, uncontrolled, severe limb infection or septicemia, such as fever exceeding 38.5°C, a white blood cell count above 15,000 cells/µL, or hypotension, at the time of screening (this does not include osteomyelitis confined to the phalanges or metatarsal heads or foot cellulitis treatable with IV antibiotics at the time of revascularization)
  • Age <18 years
  • Patients with major tissue loss (Rutherford 6) in whom major amputation was planned at the time of screening
  • Recent acute limb ischemia events within 2 weeks of screening
  • Unstable hemodynamics after the index revascularization procedure
  • Any contraindication or known intolerance to colchicine
  • Requirement for colchicine for another indication
  • Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception
  • Life expectancy <1 year

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease, a condition in which narrowed or blocked arteries reduce blood flow to the legs. People with CLTI may have severe leg pain at rest, non-healing wounds, or gangrene, and face a high risk of leg amputation and death. Even after successful procedures to restore blood flow to the leg (called revascularization), many patients still experience serious complications. Inflammation in the blood vessels is believed to play an important role in these poor outcomes.

A teljes eredeti leírásKevesebb

Colchicine is an anti-inflammatory medication that has been used safely for decades to treat gout and other inflammatory conditions. Recent large clinical trials have shown that a low dose of colchicine (0.5 mg per day) can reduce heart attacks and strokes in patients with coronary artery disease. However, it has not been studied in patients with CLTI.

The CIRCLE-Asia trial (Colchicine in Chronic Limb-Threatening Ischemia for Reduction of Complications and Limb Events in Asia) is a pilot study designed to evaluate whether colchicine can improve outcomes in patients with CLTI who have recently undergone a successful procedure to restore blood flow to their leg. Treatment begins within 7 days of the procedure.

This is a randomized, double-blind, placebo-controlled, multicenter trial conducted at five hospitals in Taiwan. A total of 200 adult patients with CLTI who have undergone successful revascularization will be randomly assigned in a 1:1 ratio to receive either colchicine 0.5 mg once daily or a matching placebo pill, in addition to their usual medications, for 12 months. Neither the patients nor the study doctors will know which treatment each patient receives.

The main outcome of interest is amputation-free survival, defined as the time until major amputation of the affected leg (above the ankle) or death from any cause, over 12 months of follow-up. The study will also assess other important outcomes including major limb complications, heart attacks, strokes, wound healing, changes in blood flow measurements, inflammatory blood markers, quality of life, and medication safety.

This pilot trial will provide the first randomized evidence on the potential benefits and safety of colchicine in CLTI patients and will help inform the design of a larger definitive trial.

A vizsgálat 2 csoportja

  • ColchicineA vizsgált kezelés

    Colchicine 0.5 mg per tab, taken 1 tab daily

    Kezelés: Colchicine 0.5 MG Oral Tablet Once Daily

  • PlaceboPlacebo, összehasonlításként

    Placebo tablets matching in appearance with study drug, taken 1 tab per day

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Colchicine in Chronic Limb-Threatening Ischemia for Reduction of Complications and Limb Events in Asia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. július 14.